Psoriatic Arthritis (PsA)
34
15
16
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.9%
1 terminated out of 34 trials
87.5%
+1.0% vs benchmark
18%
6 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (34)
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
Oxidative Stress in Autoimmune Rheumatic Diseases
APACHE Cohort (A Psoriatic Arthritis CoHort)
A Randomized, Double-blind Clinical Trial on the Efficacy of a Dietary Formulation Containing Medium-chain Triglycerides (MCT) and Fiber in Patients With Psoriatic Arthritis
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Preventing Structural Damage in Early Psoriatic Arthritis
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)